BABIO Introduces 4-in-1 SARS-CoV-2 / Flu A&B / RSV Rapid Antigen Test for Global Respiratory Outbreak Control

With respiratory infections rising across Europe, the United States, Africa, and Southeast Asia, clinicians are facing increasing challenges in distinguishing COVID-19, influenza, and RSV—three viruses with nearly identical symptoms. To support faster diagnosis and efficient patient triage, BABIO (Babio Biotechnology), a recognized Chinese manufacturer of rapid diagnostic solutions, has launched its Combo SARS-CoV-2 / Flu A & B / RSV Antigen Rapid Test Kit (Colloidal Gold Method).

This versatile 4-in-1 rapid test delivers simultaneous detection of SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) within 15 minutes, making it ideal for hospitals, community clinics, airports, emergency departments, and point-of-care environments worldwide. By combining four high-priority respiratory pathogens in one device, the kit helps reduce misdiagnosis, speeds clinical decisions, and improves outbreak control efficiency.

Engineered with high-performance monoclonal antibody technology and intuitive visual result lines, the test provides accurate, easy-to-interpret results without laboratory instruments or specialized training. The kit includes all required components and is available in multiple packaging formats to meet diverse regional and clinical needs.

As one of China’s leading manufacturers of rapid diagnostic reagents, BABIO continues to expand global partnerships, supporting healthcare providers with reliable solutions for respiratory disease management.
For more details or cooperation inquiries, please visit the official website: https://www.babiocorp.com

#RespiratoryTesting #COVID19Test #FluTest #RSVTest #ComboRapidTest #BABIO #PointOfCareTesting #MedicalDiagnostics #GlobalHealth #InfectiousDiseases